Research Paper Volume 15, Issue 19 pp 10453—10472
An immune signature to predict the prognosis of ATRX-wildtype glioma patients and guide immune checkpoint blockade therapy
Figure 6. Validation of the applicability of the risk model in the test cohort of ATRX-wt glioma patients. (A) ATRX-wt glioma patients in the test cohort were divided into high- and low-risk-score groups based on the median risk score. (B) Survival differences between ATRX-wt glioma patients in the high- and low-risk-score groups in the test cohort. (C–E) Prognostic value of the risk model for one-, three- and five-year survival in ATRX-wt glioma patients in the test cohort. (F) Deaths of ATRX-wt glioma patients in the high- and low-score groups in the test cohort (green dots represent living cases; red dots represent dead cases). (G) Expression of HOXA5, PTPN2, WT1, HOXD10, POSTN, ADAMDEC1 and MYBPH in glioma patients in the high- and low-risk-score groups of the test cohort.